ENTRY       D12500                      Drug
NAME        Etranacogene dezaparvovec (USAN/INN);
            Etranacogene dezaparvovec-drlb;
            Hemgenix (TN)
PRODUCT     HEMGENIX (CSL Behring)
CLASS       Blood modifier agent
             DG02016  Hemostatics
              DG02014  Blood coagulation accelerant
               DG02013  Blood coagulation factor
REMARK      Product: D12500<US>
EFFICACY    Bleeding suppressant
  DISEASE   Hemophilia B, congenital Factor IX deficiency [DS:H00219]
  TYPE      Gene therapy product
COMMENT     Adeno-associated virus serotype 5 (AAV5) based gene therapy designed to deliver a copy of a gene encoding the Padua variant of human coagulation Factor IX
TARGET      F9 [HSA:2158] [KO:K01321]
  PATHWAY   hsa04610(2158)  Complement and coagulation cascades
INTERACTION  
BRITE       Drug groups [BR:br08330]
             Blood modifier agent
              DG02016  Hemostatics
               DG02014  Blood coagulation accelerant
                DG02013  Blood coagulation factor
                 D12500  Etranacogene dezaparvovec
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                F9
                 D12500  Etranacogene dezaparvovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12500
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12500
             Cellular and gene therapy products
              D12500
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12500
DBLINKS     CAS: 2156583-26-3
///
